These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 8587097)

  • 1. ARAMIS and toxicity measurement. (Arthritis Rheumatism and Aging Medical Information System).
    Fries JF
    J Rheumatol; 1995 May; 22(5):995-7. PubMed ID: 8587097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arthritis, Rheumatism and Aging Medical Information System Post-Marketing Surveillance Program.
    Singh G
    J Rheumatol; 2001 May; 28(5):1174-9. PubMed ID: 11361209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NSAID induced gastrointestinal complications: the ARAMIS perspective--1997. Arthritis, Rheumatism, and Aging Medical Information System.
    Singh G; Rosen Ramey D
    J Rheumatol Suppl; 1998 May; 51():8-16. PubMed ID: 9596549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study.
    Singh G; Ramey DR; Morfeld D; Shi H; Hatoum HT; Fries JF
    Arch Intern Med; 1996 Jul; 156(14):1530-6. PubMed ID: 8687261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of NSAID induced gastrointestinal complications.
    Singh G; Triadafilopoulos G
    J Rheumatol Suppl; 1999 Apr; 56():18-24. PubMed ID: 10225536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety issues related to DMARD therapy.
    Fries JF
    J Rheumatol Suppl; 1990 Nov; 25():14-7. PubMed ID: 2273518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].
    Dammann HG
    Z Gastroenterol; 1999 Jan; 37(1):45-58. PubMed ID: 10091284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Vioxx fallout.
    Palmer K
    Minn Med; 2005 Mar; 88(3):26-30. PubMed ID: 15852592
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety of conventional drugs and biologic agents for Rheumatoid Arthritis.
    Amoroso A; Gigante A; Gianni C; Amoroso D; Zennaro D; Galluzzo S; Caccavo D
    Eur Rev Med Pharmacol Sci; 2003; 7(5):139-45. PubMed ID: 15214589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Forthcoming non-steroidal anti-inflammatory drugs: are they really devoid of side effects?
    Bjarnason I
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S27-36. PubMed ID: 10379467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reporting of fatal adverse drug reactions.
    Liu BA; Knowles SR; Mittmann N; Einarson T; Shear NH
    Can J Clin Pharmacol; 2001; 8(2):84-8. PubMed ID: 11493936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relative toxicity of nonsteroidal antiinflammatory drugs.
    Fries JF; Williams CA; Bloch DA
    Arthritis Rheum; 1991 Nov; 34(11):1353-60. PubMed ID: 1953813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios.
    van der Heijden PG; van Puijenbroek EP; van Buuren S; van der Hofstede JW
    Stat Med; 2002 Jul; 21(14):2027-44. PubMed ID: 12111885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions.
    Blomqvist P; Feltelius N; Ekbom A; Klareskog L
    J Rheumatol; 2000 May; 27(5):1171-7. PubMed ID: 10813283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The safety profile of anti-rheumatic drugs in long-term use].
    Kurowski M
    Verh Dtsch Ges Inn Med; 1989; 95():704-6. PubMed ID: 2603506
    [No Abstract]   [Full Text] [Related]  

  • 16. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
    DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
    Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New drugs require nw follow-up surveillance].
    Feltelius N; Lindblad S
    Lakartidningen; 2001 Feb; 98(9):951-3. PubMed ID: 11292975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacovigilance as new direction of research].
    Gaszner G; Makkos Z; Gaszner P
    Neuropsychopharmacol Hung; 2005 Dec; 7(4):194-8. PubMed ID: 16496484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact on health-related quality of life from non-steroidal anti-inflammatory drugs, methotrexate, or steroids in treatment for juvenile idiopathic arthritis.
    Riddle R; Ryser CN; Morton AA; Sampson JD; Browne RH; Punaro MG; Gatchel RJ
    J Pediatr Psychol; 2006 Apr; 31(3):262-71. PubMed ID: 15872147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis.
    Inotai A; Mészáros A
    Int J Technol Assess Health Care; 2009 Apr; 25(2):190-5. PubMed ID: 19366498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.